Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

4D Molecular Therapeutics, Inc. (FDMT) vs Gyre Therapeutics, Inc. (GYRE)

4D Molecular Therapeutics, Inc. and Gyre Therapeutics, Inc. are both Biotechnology companies. 4D Molecular Therapeutics, Inc. and Gyre Therapeutics, Inc. are of similar size ($807.1M and $777.2M). 4D Molecular Therapeutics, Inc. grew revenue faster over the last twelve months: 278,712.1% against 10.7%. Gyre Therapeutics, Inc. has the higher net margin (−13.7% vs −194.7%) and the higher return on invested capital (−8.51% vs −186.9%). Across the 18 metrics below, Gyre Therapeutics, Inc. leads on 12 and 4D Molecular Therapeutics, Inc. on 6.

Valuation

Metric FDMT GYRE Biotechnology median
P/E n/m n/m 7.88
P/S 11.05 6.35 11.47
P/B 2.49 5.19 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 7.34 5.71 10.73
Earnings yield (18.18%) (2.72%) (28.84%)
Free cash flow yield (15.34%) (0.96%) (23.03%)

Profitability

Metric FDMT GYRE Biotechnology median
Gross margin 100.00% 94.15% 65.16%
Operating margin (214.24%) (10.53%) 0.00%
Net margin (194.74%) (13.73%) 0.00%
Free cash flow margin (169.51%) (6.12%) 0.00%
Return on equity (43.25%) (11.75%) (57.72%)
Return on assets (37.09%) (9.08%) (49.22%)
Return on invested capital (186.91%) (8.51%) 0.00%

Growth

Metric FDMT GYRE Biotechnology median
Revenue growth (TTM) 278,712.12% 10.72% 5.64%
EPS growth (last fiscal year) 18.79% (60.00%) —
Revenue growth, 5-year CAGR 44.32% 40.96% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric FDMT GYRE Biotechnology median
Debt to equity 0.05 0.00 0.00
Current ratio 8.03 4.26 4.73
Net debt to EBITDA 2.52 (3.74) 0.96

Dividend

Metric FDMT GYRE Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric FDMT GYRE Biotechnology median
Market cap 807.12m 777.23m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack